Navigating Refractory RCC: Insights from the TiNivo-2 Trial
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.
Related Articles
Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents
The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib,…
2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer
Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.
UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC
Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.
Acute myeloid leukemia with BCL6 and KMT2A dual rearrangements
A 2-year-old boy was diagnosed with acute myeloid leukemia (AML) with t(10;11)(p12.31;q23.3)/ KMT2A:: MLLT10 rearrangement. Despite 5 lines of treatment, including a menin inhibitor and…
Dr Al Malki on Reducing Relapse Risk in Patients Undergoing Haplo-HSCT
Monzr M. Al Malki, MD, discusses reducing relapse risk in patients undergoing haploidentical hematopoietic stem cell transplantation.
LaCasce on Bispecific Antibodies Transforming Lymphoma Care
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.
Everolimus Plus Lanreotide Extends PFS in Advanced GEP-NETs
Everolimus plus lanreotide demonstrated an improved PFS compared with everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.
The Democrats Show Why They Lost
At a meeting of the DNC, the party seemed to be at pains to demonstrate that it learned nothing from its 2024 defeat. February 02,…
AVA6000 Elicits Clinically Meaningful Tumor Shrinkage in Salivary Gland Cancer
Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.